252 related articles for article (PubMed ID: 16636895)
1. Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype.
Baba F; Swartz K; van Buren R; Eickhoff J; Zhang Y; Wolberg W; Friedl A
Breast Cancer Res Treat; 2006 Jul; 98(1):91-8. PubMed ID: 16636895
[TBL] [Abstract][Full Text] [Related]
2. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis.
Barbareschi M; Maisonneuve P; Aldovini D; Cangi MG; Pecciarini L; Angelo Mauri F; Veronese S; Caffo O; Lucenti A; Palma PD; Galligioni E; Doglioni C
Cancer; 2003 Aug; 98(3):474-83. PubMed ID: 12879463
[TBL] [Abstract][Full Text] [Related]
3. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells.
Matsuda K; Maruyama H; Guo F; Kleeff J; Itakura J; Matsumoto Y; Lander AD; Korc M
Cancer Res; 2001 Jul; 61(14):5562-9. PubMed ID: 11454708
[TBL] [Abstract][Full Text] [Related]
4. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
5. Developmental and FGF-2-mediated regulation of syndecans (1-4) and glypican in oligodendrocytes.
Bansal R; Kumar M; Murray K; Pfeiffer SE
Mol Cell Neurosci; 1996 Apr; 7(4):276-88. PubMed ID: 8793863
[TBL] [Abstract][Full Text] [Related]
6. Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer.
Davies EJ; Blackhall FH; Shanks JH; David G; McGown AT; Swindell R; Slade RJ; Martin-Hirsch P; Gallagher JT; Jayson GC
Clin Cancer Res; 2004 Aug; 10(15):5178-86. PubMed ID: 15297422
[TBL] [Abstract][Full Text] [Related]
7. Association of syndecan-1 with tumor grade and histology in primary invasive cervical carcinoma.
Rintala M; Inki P; Klemi P; Jalkanen M; Grénman S
Gynecol Oncol; 1999 Dec; 75(3):372-8. PubMed ID: 10600292
[TBL] [Abstract][Full Text] [Related]
8. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
10. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological study of the expression of syndecan-1 in invasive breast carcinomas. correlation with extracellular matrix components.
Tsanou E; Ioachim E; Briasoulis E; Charchanti A; Damala K; Karavasilis V; Pavlidis N; Agnantis NJ
J Exp Clin Cancer Res; 2004 Dec; 23(4):641-50. PubMed ID: 15743035
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma.
Suthipintawong C; Wejaranayang C; Vipupinyo C
J Med Assoc Thai; 2008 Dec; 91(12):1779-84. PubMed ID: 19133508
[TBL] [Abstract][Full Text] [Related]
13. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
Sharif MA; Mamoon N; Mushtaq S; Khadim MT
J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313
[TBL] [Abstract][Full Text] [Related]
14. Localisation of specific heparan sulfate proteoglycans during the proliferative phase of brain development.
Ford-Perriss M; Turner K; Guimond S; Apedaile A; Haubeck HD; Turnbull J; Murphy M
Dev Dyn; 2003 Jun; 227(2):170-84. PubMed ID: 12761845
[TBL] [Abstract][Full Text] [Related]
15. Syndecan-1 expression has prognostic significance in head and neck carcinoma.
Anttonen A; Kajanti M; Heikkilä P; Jalkanen M; Joensuu H
Br J Cancer; 1999 Feb; 79(3-4):558-64. PubMed ID: 10027330
[TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcome.
Harigopal M; Heymann J; Ghosh S; Anagnostou V; Camp RL; Rimm DL
Breast Cancer Res Treat; 2009 May; 115(1):77-85. PubMed ID: 18521745
[TBL] [Abstract][Full Text] [Related]
17. Heparan sulfate proteoglycan expression in chronic cholestatic human liver diseases.
Roskams T; Rosenbaum J; De Vos R; David G; Desmet V
Hepatology; 1996 Sep; 24(3):524-32. PubMed ID: 8781318
[TBL] [Abstract][Full Text] [Related]
18. Short-term biologic response to withdrawal of hormone replacement therapy in patients with invasive breast carcinoma.
Prasad R; Boland GP; Cramer A; Anderson E; Knox WF; Bundred NJ
Cancer; 2003 Dec; 98(12):2539-46. PubMed ID: 14669271
[TBL] [Abstract][Full Text] [Related]
19. Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast.
Lee A; Park WC; Yim HW; Lee MA; Park G; Lee KY
Jpn J Clin Oncol; 2007 Sep; 37(9):708-14. PubMed ID: 17940078
[TBL] [Abstract][Full Text] [Related]
20. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
